Commentary: SGLT2is vs. GLP1RAs reduce cardiovascular and all-cause mortality

Lixin Du1†, Jiao Qin1†, Dengchuan Wang2, Yunhui Zhao1, Ning Xu3 and Chaowen Wu3

1Department of Medical Imaging, Shenzhen Longhua District Central Hospital, Shenzhen, China, 2Office of Medical Ethics, Shenzhen Longhua District Central Hospital, Shenzhen, China, 3Department of Endocrinology, Shenzhen Longhua District Central Hospital, Shenzhen, China

*CORRESPONDENCE
Lixin Du
dulixin976@yeah.net
†These authors have contributed equally to this work

KEYWORDS
cardiovascular, renal, death, type 2 diabetes, SGLT 2 inhibitors, GLP-1RAs

Introduction

By implementing a meta-analysis (1) based on nine large cohort studies (2–10) directly comparing cardiovascular and renal endpoints between sodium-glucose cotransporter 2 inhibitors (SGLT2is) and glucagon-like peptide 1 receptor agonists (GLP1RAs) in patients with type 2 diabetes (T2D), Qiu et al. (1) identified an interesting and clinically relevant finding that compared with GLP1RAs, SGLT2is were associated with significantly decreased risks of cardiovascular death (CVDH) [hazard ratio (HR) 0.82, 95% confidence interval (CI) 0.68–0.99] and all-cause mortality (ACM) (HR 0.92, 95% CI 0.85–0.99). Nowadays, nine new relevant cohort studies (11–19) are available and yield some inconsistent findings. For example, the studies by Fu et al. (11) and Ueda et al. (12) show similar risk of CVDH between SGLT2is and GLP1RAs, while the studies by Alkabbani et al. (13) and Tang et al. (14) show similar risk of ACM. Moreover, in Qiu's et al. (1) meta-analysis only a few of studies were incorporated when some endpoints were assessed, such as composite kidney outcome (CKO). This also suggests the necessity of performing an updated meta-analysis in which more studies could be included in order to provide greater statistical power. Hence, we carried out an updated meta-analysis and aimed at confirming and updating the findings of Qiu's et al. (1) meta-analysis.

Methods

We conducted this updated meta-analysis in accordance with the statement of Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) (20).
The studies eligible for inclusion were cohort studies directly comparing SGLT2is and GLP1RAs in cardio-renal endpoints in T2D patients. Seven endpoints of interest are the same as those in Qiu et al. (1) meta-analysis: stroke, hospitalization for heart failure (HHF), CKO, major adverse cardiovascular events (MACE), myocardial infarction (MI), CVDH, and ACM. CKO was defined as a composite of eGFR 50% reduction or lower than 60 ml/min/1.73 m², micro- or macro-albuminuria, renal failure, dialysis, renal transplantation, or renal death; and MACE was defined as a composite of CVDH, MI, or stroke. We searched PubMed, Embase, and Web of science from inception date to May 2022. The whole search expression is (using PubMed as an example): ["Diabetes Mellitus, Type 2" (Mesh) OR "diabetes" (all fields)] AND [Sodium-Glucose Transporter 2 Inhibitors (MH) OR "Sodium glucose transporter 2 inhibitor∗" (TIAB) OR "Sodium glucose cotransporter 2 inhibitor∗" (TIAB) OR "Sodium glucose co-transporter 2 inhibitor∗" (TIAB) OR "SGLT∗" (TIAB) OR Gliflozin (tiab) OR "Empagliflozin" (tiab) OR "Dapagliflozin" (tiab) OR "Canagliflozin" (tiab) OR "ertugliflozin" (tiab) OR "sotagliflozin" (tiab)] AND ["glucagon-like peptide 1 receptor agonist∗" (TIAB) OR "GLP1∗" (TIAB) OR lixinenatide (TIAB) OR liraglutide (TIAB) OR semaglutide (TIAB) OR exenatide (TIAB) OR albiglutide (TIAB) OR dulaglutide (TIAB) OR Efpeglenatide (TIAB)] AND ["cardiovascular" (tiab) OR "cardiac" (tiab) OR "heart failure" (tiab) OR "myocardial infarction" (TIAB) OR stroke (tiab) OR "MACE" (tiab) OR "Kidney" (tiab) OR "renal" (tiab) OR "CKD" (tiab) OR "ESRD" (tiab) OR "ESKD" (tiab) OR "cardiorenal" (tiab) OR "death" (tiab) OR "mortality" (tiab)] AND ["cohort study" (tiab) OR "observational study" (tiab) OR "real world" (tiab) OR "real-world" (tiab)].

The outcome data were extracted from included studies independently by two authors, and any discrepancies between them were solved by discussing with a third author. Just like Qiu et al. (1), we performed random-effects meta-analyses based on HRs and 95% CIs to derive conservative estimates for the relative effectiveness of SGLT2is and GLP1RAs. $P < 0.05$ was considered as statistical significance. All statistical analyses were done using Stata/MP (Version 16.0).

Findings and implications

In this updated meta-analysis, we included a total of eighteen large cohort studies (2–19). We identified that compared with GLP1RAs, SGLT2is were associated with a 10% increase in risk of stroke (HR 1.10, 95% CI 1.01–1.19; $P$ for effect size = 0.04; Figure 1A), a 21% reduction in risk of HHF (HR 0.79, 95% CI 0.71–0.88; $P$ for effect size < 0.01; Figure 1B), and a 17% reduction in risk of CKO (HR 0.83, 95% CI 0.70–0.99; $P$ for effect size = 0.04; Figure 1C). Moreover, SGLT2is and GLP1RAs had no statistically significant differences in risks of MACE (HR 1.00, 95% CI 0.95–1.04; $P$ for effect size = 0.82; Figure 1D), MI (HR 0.95, 95% CI 0.88–1.02; $P$ for effect size = 0.16; Figure 1E), CVDH (HR 0.91, 95% CI 0.81–1.02; $P$ for effect size = 0.11; Figure 1F), and ACM (HR 0.95, 95% CI 0.90–1.00; $P$ for effect size = 0.06; Figure 1G).

This updated meta-analysis revealed that SGLT2is vs. GLP1RAs were associated with significantly decreased risks of HHF and CKO and significantly increased risk of stroke in T2D patients, whereas these two drug classes had similar risks of MACE, MI, CVDH, and ACM. Substantially different with these findings, the main findings in the previous meta-analysis (1) by Qiu et al. are that SGLT2is vs. GLP1RAs were associated with significantly decreased risks of CVDH and ACM whereas they had similar risks of CKO and stroke. Obviously, our meta-analysis included more studies (a total of 18 studies) than Qiu’s et al. (1) meta-analysis did (a total of 9 studies), and accordingly substantially updated Qiu’s et al. findings.

Although this meta-analysis is an update for Qiu’s et al. (1) meta-analysis, this is the first one that identified the significant differences between SGLT2is and GLP1RAs in risks of HHF, CKO, and stroke by incorporating real-world studies. Moreover, several previous network meta-analyses (21–24) based on placebo-controlled, cardiovascular/renal outcome, randomized trials revealed that SGLT2is were superior to GLP1RAs in reducing HHF and composite renal outcome, GLP1RAs but not SGLT2is could reduce stroke, and no significant differences existed in the other cardiovascular and death outcomes between them. Obviously, these findings are almost completely consistent with our findings. Therefore, our findings would further help to select between SGLT2is and GLP1RAs for prevention of HHF, CKO, and stroke in T2D patients. Concretely speaking, SGLT2is should be considered over GLP1RAs as for preventing heart failure and renal failure events, whereas GLP1RAs should be considered over SGLT2is as for preventing stroke. What is worth mentioning, although it is important to select the best option upon different patient characteristics and prevention of different cardio-renal outcomes, both of the two drug classes remain the best therapeutic option for T2D patients due to their long-term cardio-renal benefits (25). Due to the absence of original individual patient data, we failed to explore the impact of relevant patient characteristics (e.g., age, sex, and history of cardio-renal disease) on the relative efficacy of SGLT2is vs. GLP1RAs. These possible modifying factors need to be tested in future research. Another limitation of this meta-analysis is only assessing total stroke but failing to assess ischemic and...
FIGURE 1  
Forest plots of meta-analysis on stroke (A), hospitalization for heart failure (B), composite kidney outcome (C), major adverse cardiovascular events (D), myocardial infarction (E), cardiovascular death (F), and all-cause mortality (G). SGLT2is, sodium-glucose cotransporter 2 inhibitors; GLP1RAs, glucagon-like peptide 1 receptor agonists; CI, confidence interval.

hemorrhagic strokes, respectively. Further studies filling this knowledge gap are clinically meaningful.

In conclusion, this updated meta-analysis identified that SGLT2is vs. GLP1RAs were associated with significantly decreased risks of HHF and CKO and significantly increased risk of stroke in T2D patients, whereas they had similar risks of the other cardiovascular and death outcomes. These substantially updated the findings of Qiu’s et al. (1) meta-analysis, and would further help to select between SGLT2is and GLP1RAs for prevention of specific cardio-renal events in T2D patients.

Summary

Qiu et al. (1) implemented a meta-analysis based on nine cohort studies directly comparing cardiovascular and renal endpoints between sodium-glucose cotransporter 2 inhibitors
(SGLT2is) and glucagon-like peptide 1 receptor agonists (GLP1RAs) in patients with type 2 diabetes (T2D). Nowadays, nine new relevant cohort studies are available and yield some inconsistent findings. Hence, we did an updated meta-analysis by including 18 large cohort studies. We identified that SGLT2is vs. GLP1RAs were associated with significantly decreased risks of hospitalization for heart failure (HHF) and composite kidney outcome (CKO) and significantly increased risk of stroke in T2D patients, whereas they had similar risks of the other cardiovascular and death outcomes. This meta-analysis is the first one that identified the significant differences between SGLT2is and GLP1RAs in risks of HHF, CKO, and stroke by incorporating real-world studies. Our findings substantially updated the findings of Qiu’s et al. (1) meta-analysis, and would further help to select between SGLT2is and GLP1RAs for prevention of specific cardio-renal events in T2D patients.

Author contributions
LD: design, YZ, NX, and CW: conduct/data collection. JQ and DW: analysis. LD and JQ: writing manuscript. All authors approved the manuscript.

References
1. Qiu M, Wei XB, Wei W. SGLT2is vs. GLP1RAs reduce cardiovascular and all-cause mortality. Front Cardiovasc Med. (2021) 8:791311. doi: 10.3389/fcvm.2021.79 1311
2. Patorno E, Pawar A, Besette LG, Kim DH, Dave C, Glynn RJ, et al. Comparative effectiveness and safety of sodium-glucose co-transporter 2 inhibitors versus glucagon-like peptide 1 receptor agonists in older adults. Diabetes Care. (2021) 44:826–35. doi: 10.2337/dc20-1464
3. Luger M, Sattar N, Miftaraj M, Ekelund J, Franzen S, Svensson AM, et al. Cardiovascular and other diabetes related outcomes with SGLT-2 inhibitors compared to GLP-1 receptor agonists in type 2 diabetes: nationwide observational study. Cardiovasc Diabetol. (2021) 20:67. doi: 10.1186/s12933-021-01258-x
4. Nørgaard CH, Starklop L, Gerda TA, Vestergaard P, Bonde AN, Fosbol E, et al. Cardiovascular outcomes with GLP-1 receptor agonists versus SGLT 2 inhibitors in patients with type 2 diabetes. Eur Heart J Cardiovasc Pharmacother. (2021) 2-pvab053. doi: 10.1093/ehjcp/pvab053
5. Thomsen RW, Knudsen JS, Kahlert J, Bagger JS, Møller PH, et al. Cardiovascular events, acute hospitalizations, and mortality in patients with type 2 diabetes mellitus who initiate empagliflozin versus liraglutide: a comparative effectiveness study. J Am Heart Assoc. (2021) 10:e19356. doi: 10.1161/JAHA.120.019356
6. Poonawalla JB, Bowe AT, Tindal MC, Meah YA, Schwab P. A real-world comparison of cardiovascular, medical and costs outcomes in new users of SGLT2 inhibitors versus GLP-1 agonists. Diabetes Res Clin Pract. (2021) 175:108800. doi: 10.1016/j.diabres.2021.108800
7. Pineda ED, Liao JC, Godley PJ, Michel JB, Rascati KL. Cardiovascular outcomes among patients with type 2 diabetes newly initiated on sodium-glucose co-transporter-2 inhibitors, glucagon-like peptide-1 receptor agonists, and other antidiabetic medications. J Manag Care Spec Pharm. (2020) 26:610–8. doi: 10.18553/jmcp.2020.26.6.510
8. Xie Y, Bowe B, Gibson AK, McGill JR, Madduuri G, Yan Y, et al. Comparative effectiveness of SGLT2 inhibitors, GLP-1 receptor agonists, DPP-4 inhibitors, and sulfonylurea on risk of kidney outcomes: emulation of a target trial using health care databases. Diabetes Care. (2020) 43:2859–69. doi: 10.2337/dc20-1890
9. Longato E, Di Camillo B, Sparacino G, Guibian L, Avogaro A, Fadini GP. Cardiovascular outcomes of type 2 diabetic patients treated with SGLT-2 inhibitors versus GLP-1 receptor agonists in real-life. BMJ Open Diabetes Res Care. (2020) 8:e001451. doi: 10.1136/bmjdrc-2020-001451
10. Patorno E, Goldfine AB, Schneeweiss S, Everett BM, Glynn R, Liu J, et al. Cardiovascular outcomes associated with canagliflozin versus other non-gliflozin antidiabetic drugs: population based cohort study. BMJ. (2018) 360:k119. doi: 10.1136/bmj.k119
11. Fu EL, Clase CM, Jane RJ, Lindholm B, Dekker FW, Jardine MJ, et al. Comparative effectiveness of SGLT2i versus GLP-1RA on cardiovascular outcomes in routine clinical practice. Int J Cardiol. (2022) 352:172–9. doi: 10.1016/j.ijcard.2021.02.042
12. Ueda P, Wintzell V, Dahlqvist E, Eliasson B, Svensson AM, Franzen S, et al. Comparative cardiovascular and renal effectiveness of sodium-glucose co-transporter 2 inhibitors and glucagon-like peptide 1 receptor-agonists: scandinavian cohort study. Diabetes Obes Metab. (2021) 24:473–85. doi: 10.1111/dob.14598
13. Alkabbani W, Gamble JM, Eurich DT, Minhas-Sandhu JK, Shah BR, Alsabbagh MW, et al. Risk of hospitalization and death associated with sodium glucose co-transporter-2 inhibitors: a comparison with five other classes of antidiabetic drugs. Diabetes Metab. (2022) 48:10365. doi: 10.1016/j.diabet.2021.101305
14. Tang E, Wong C, Lau K, Fei Y, Cheung B. Cardio-renal outcomes and the direct medical cost of type 2 diabetes patients treated with sodium-glucose co-transporter-2 inhibitors and glucagon-like peptide-1 receptor agonists versus sodium-glucose co-transporter-2 inhibitors and glucagon-like peptide-1 receptor agonists: a population-based cohort study. Diabetes Res Clin Pract. (2021) 190:109671. doi: 10.1016/j.diabres.2021.109671
15. Dong YH, Chang CH, Lin JW, Yang WS, Wu LC, Toh S. Comparative cardiovascular effectiveness of glucagon-like peptide-1 receptor agonists versus sodium-glucose co-transporter-2 inhibitors in patients with type 2 diabetes: a population-based cohort study. Diabetes Obes Metab. (2022) 24:1623–37. doi: 10.1111/dob.14741
16. Lyu B, Grams ME, Chang A, Inker LA, Correes J, Shin JJ. Sodium-Glucose co-transporter 2 inhibitors, glucagon-like-peptide-1 receptor agonists, and

Funding
This work was supported by the Key Laboratory of Neuroimaging, Longhua District, Shenzhen; and Shenzhen Fundamental Research Program (Natural Science Foundations), General Programe for Fundamental Research (Grant No. JCYJ20210324142404012).

Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
17. Hsiao FC, Lin CP, Tung YC, Wu CT, Chu PH. Major adverse limb events in type 2 diabetes patients receiving glucagon-like peptide-1 receptor agonists versus sodium-glucose cotransporter 2 inhibitors: a retrospective multi-institutional study. *Diabetes Res Clin Pract.* (2021) 180:109076. doi: 10.1016/j.diabres.2021.109076

18. Patorno E, Htoo PT, Glynn RJ, Schneeweiss S, Wexler DJ, Pawar A, et al. Sodium-Glucose cotransporter-2 inhibitors versus glucagon-like peptide-1 receptor agonists and the risk for cardiovascular outcomes in routine care patients with diabetes across categories of cardiovascular disease. *Ann Intern Med.* (2021) 174:1528–41. doi: 10.7326/M21-0893

19. DeRemer CE, Youyi SM, Guo J, Donahoo WT, Winterstein AG, Shao H. Comparing cardiovascular benefits between GLP-1 receptor agonists and SGLT2 inhibitors as an add-on to metformin among patients with type 2 diabetes: a retrospective cohort study. *J Diabetes Complications.* (2021) 35:107972. doi: 10.1016/j.jdiacomp.2021.107972

20. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *PLoS Med.* (2009) 6:e1000097. doi: 10.1371/journal.pmed.1000097

21. Lin DS, Lee JK, Hung CS, Chen WJ. The efficacy and safety of novel classes of glucose-lowering drugs for cardiovascular outcomes: a network meta-analysis of randomized clinical trials. *Diabetologia.* (2021) 64:2676–86. doi: 10.1007/s00125-021-05529-w

22. Fei Y, Tsoi ME, Cheung B. Cardiovascular outcomes in trials of new antidiabetic drug classes: a network meta-analysis. *Cardiovasc Diabetol.* (2019) 18:112. doi: 10.1186/s12933-019-0916-z

23. Giugliano D, Longo M, Signorelli S, Maiorino MI, Solerte S, Chioldini P, et al. The effect of DPP-4 inhibitors, GLP-1 receptor agonists and SGLT-2 inhibitors on cardiorenal outcomes: a network meta-analysis of 23 CVOTs. *Cardiovasc Diabetol.* (2022) 21:42. doi: 10.1186/s12933-022-01474-z

24. Palmer SC, Tendal B, Mustafa RA, Vandvik PO, Li S, Hao Q, et al. Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials. *BMJ.* (2021) 372:m4573. doi: 10.1136/bmj.m4573

25. Buse JB, Wexler DJ, Tsapas A, Rossing P, Mingrone G, Mathieu C, et al. 2019 Update to: management of hyperglycemia in type 2 diabetes. 2018 a consensus report by the American diabetes association (ADA) and the European association for the study of diabetes (EASD). *Diabetes Care.* (2020) 43:487–91. doi: 10.2337/dc19-0066